Axon Enterprise, Inc. (NASDAQ:AXON) is Groupama Asset Managment’s 10th Largest Position

Groupama Asset Managment increased its position in shares of Axon Enterprise, Inc. (NASDAQ:AXON) by 0.3% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 501,260 shares of the biotechnology company’s stock after purchasing an additional 1,260 shares during the period. Axon Enterprise accounts for about 2.2% of Groupama Asset Managment’s holdings, making the stock its 10th biggest holding. Groupama Asset Managment owned approximately 0.66% of Axon Enterprise worth $297,909,000 at the end of the most recent reporting period.

A number of other institutional investors also recently bought and sold shares of AXON. Vanguard Group Inc. raised its position in shares of Axon Enterprise by 3.4% during the 4th quarter. Vanguard Group Inc. now owns 8,446,437 shares of the biotechnology company’s stock valued at $5,019,886,000 after buying an additional 275,959 shares during the period. Geode Capital Management LLC lifted its stake in shares of Axon Enterprise by 3.7% in the 4th quarter. Geode Capital Management LLC now owns 1,847,925 shares of the biotechnology company’s stock valued at $1,095,542,000 after purchasing an additional 65,097 shares during the last quarter. Alliancebernstein L.P. grew its holdings in shares of Axon Enterprise by 273.8% during the 4th quarter. Alliancebernstein L.P. now owns 1,109,045 shares of the biotechnology company’s stock worth $659,128,000 after purchasing an additional 812,337 shares during the period. Norges Bank purchased a new position in shares of Axon Enterprise during the 4th quarter worth $482,081,000. Finally, GQG Partners LLC acquired a new stake in shares of Axon Enterprise during the 4th quarter worth about $478,349,000. 79.08% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

AXON has been the topic of a number of research analyst reports. JMP Securities reissued an “outperform” rating on shares of Axon Enterprise in a research note on Tuesday, February 4th. Northcoast Research cut shares of Axon Enterprise from a “buy” rating to a “neutral” rating in a report on Wednesday, February 19th. The Goldman Sachs Group increased their price target on Axon Enterprise from $500.00 to $700.00 and gave the company a “buy” rating in a research report on Monday, January 27th. Robert W. Baird lifted their price objective on shares of Axon Enterprise from $600.00 to $800.00 and gave the stock an “outperform” rating in a research report on Friday, December 6th. Finally, Morgan Stanley upgraded shares of Axon Enterprise from an “equal weight” rating to an “overweight” rating and increased their price target for the company from $500.00 to $700.00 in a research note on Tuesday, December 3rd. One analyst has rated the stock with a sell rating, two have assigned a hold rating and eleven have assigned a buy rating to the company’s stock. According to MarketBeat.com, Axon Enterprise currently has an average rating of “Moderate Buy” and an average target price of $604.67.

Insiders Place Their Bets

In related news, Director Jeri Williams sold 307 shares of the firm’s stock in a transaction dated Monday, March 17th. The shares were sold at an average price of $552.72, for a total value of $169,685.04. Following the completion of the sale, the director now owns 1,627 shares in the company, valued at $899,275.44. This trade represents a 15.87 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Caitlin Elizabeth Kalinowski sold 450 shares of the business’s stock in a transaction dated Thursday, January 2nd. The stock was sold at an average price of $604.07, for a total transaction of $271,831.50. Following the sale, the director now directly owns 6,929 shares in the company, valued at approximately $4,185,601.03. This represents a 6.10 % decrease in their position. The disclosure for this sale can be found here. 6.10% of the stock is currently owned by company insiders.

Axon Enterprise Price Performance

Shares of NASDAQ:AXON opened at $525.95 on Tuesday. The company has a quick ratio of 2.63, a current ratio of 2.96 and a debt-to-equity ratio of 0.32. Axon Enterprise, Inc. has a 52 week low of $273.52 and a 52 week high of $715.99. The company has a market cap of $40.30 billion, a P/E ratio of 135.90, a PEG ratio of 5.17 and a beta of 1.12. The company has a 50-day moving average price of $588.26 and a 200 day moving average price of $551.61.

Axon Enterprise Profile

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.